Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01786603Phase 2Completed

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT00769860Phase 2Completed

Arimoclomol in Sporadic Inclusion Body Myositis

Role: lead

NCT00832000Phase 2Completed

Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia

Role: lead

NCT00244413Completed

Characteristics of Nondystrophic Myotonias

Role: lead

All 4 trials loaded